The mode of action of antidepressant drugs may be related to mechanisms of receptor adaptation, involving overall the serotonin 1A (5-HT "A ) receptor subtype. However, so far, the clinical effectiveness of selective compounds acting at this level has proved disappointing. This could be explained by the heterogeneity of 5-HT "A receptors within the central nervous system. In animals, two 5-HT "A agonists, flibanserin and buspirone, have shown different pharmacological properties, depending on the brain region. Since no evidence supports this observation in humans, this study sought to investigate whether these two drugs exert different effects on 5-HT "A receptor activation in three different human brain areas : the prefrontal cortex, hippocampus and raphe nuclei. 5-HT "A -mediated inhibition of forskolin-stimulated adenylyl cyclase (AC) was taken as an index of 5-HT "A receptor activation. Flibanserin significantly reduced the activity of AC post-synaptically, i.e. in the prefrontal cortex [EC &! (meanp...), 28p10n2 n ; E max , 18p2n3 %] and in the hippocampus (EC &! , 3n5p3n1 n ; E max , 20p4n0 %), but had no effect in the raphe nuclei, i.e. at pre-synaptic level. Vice versa, buspirone was only slightly but significantly effective in the raphe (EC &! , 3n0p2n8 n ; E max , 12p1n9 %). Agonist effects were sensitive to the 5-HT "A antagonists WAY-100135 and pindobind 5-HT "A in the cortex and raphe nuclei, whereas buspirone antagonized flibanserin in the hippocampus. These findings suggest a region-related action of flibanserin and buspirone on forskolin-stimulated AC activity in human brain.
Introduction
In the search for new antidepressant compounds with a short latency of action, the serotonin (5-HT) receptor subtypes are the most widely investigated and, in particular, 5-HT "A receptors, which have been found to play a key role in central serotonergic transmission (Lerer et al., 1999 ; Schreiber and De Vry, 1993) . Several lines of evidence support the role of this receptor subtype in depression : blunted physiological responses to 5-HT "A receptor agonists in vivo as well as the in-vitro changes in 5-HT "A receptor binding in post-mortem brain tissues from depressed patients (Arango et al., 1995 ; Cowen et al., 1994 ; Lesch et al., 1992 ; Meltzer and Maes, 1995 ; Shapira et al., 2000 ; Stockmeier et al., 1998) . Further, a widespread reduction of 5-HT "A receptors labelled by the selective antagonist [""C]WAY-100635 has been found in the living brain of depressed patients by positron emission tomographic scans (Drevets et al., 1999 ; Sargent et al., 2000) . The use of pindolol, a 5-HT "A pre-synaptic antagonist that leads to a direct blockade of 5-HT "A autoreceptors, has produced a faster onset of action during combination treatment with SSRIs (Artigas et al., 1996 ; Marangell, 2000 ; Zanardi et al., 1997) . In addition, selective agonists on post-synaptic 5-HT "A receptors have been proposed as potential fast-acting antidepressant drugs (Blier and De Montigny, 1994) . However, the clinical efficacy of 5-HT "A receptor agonists is controversial. Buspirone and related azapirones, proposed as both anxiolytic and antidepressant agents on the basis of their direct activation of rodent 5-HT "A receptors, have also shown a delayed therapeutic activity (Heiser and Wilcox, 1998) . This could be explained in the light of the recently suggested heterogeneity of 5-HT "A receptors. In animals, it has been observed that compounds acting on 5-HT "A receptors can exhibit different agonist\ antagonist characteristics (Borsini, 1998 ; Borsini et al., 1995a,b ; De Vry, 1995, for review ; El Mansari and Blier, 1997) . No pharmacological evidence regarding heterogeneity of 5-HT "A receptors is available for humans. Therefore, our study explored whether 5-HT "A receptors could display a pharmacological and functional heterogeneity in the human central nervous system (CNS). To achieve this aim, the effects of 5-HT "A receptor activation were investigated in post-synaptic (prefrontal cortex and hippocampus) and pre-synaptic (raphe nuclei) regions of post-mortem human brains, using buspirone and flibanserin, two 5-HT "A receptor agonists displaying different pharmacological characteristics in animals (Borsini et al., 1995a,b ; 1998) . Agonist-mediated inhibition of forskolinstimulated adenylyl cyclase (AC) activity was taken as a marker of receptor activation, since 5-HT "A receptor coupling to G proteins has been found to be resistant to post-mortem degradation (Elliott and Reynolds, 1999 ; O'Neill et al., 1991 ; Palego et al., 1997 Palego et al., , 1999 . The effects of flibanserin and buspirone were further characterized by means of selective 5-HT "A antagonists. Before performing the experiments on AC, we assessed the affinity of the various compounds for human 5-HT "A receptors using the radioligand [$H]8-hydroxy-2(di-N-propylamino) tetraline ([$H]8-OH-DPAT) in the brain regions under investigation.
Method

Human brain tissues
Brains from 20 subjects (11 men and 9 women, aged between 53 and 88 yr, meanp.., 70p9n4 yr) were collected during autopsy sessions, the post-mortem delay ranging from 16 to 65 h (meanp.., 29p12 h). All subjects had died from causes not involving the CNS, either primarily or secondarily, and whose histories excluded any evidence of psychiatric illness or treatment with psychotropic drugs at least until just prior to their death. It was not possible to check whether the subjects had taken natural agents, e.g. St. John's Wort. Causes of death were heart failure (n l 14), respiratory failure (n l 5) or lung cancer (n l 1). Prefrontal cortex (Brodmann's areas : A9 and A10), hippocampus and raphe nuclei at ponto-mesencephalic level were identified and collected by pathologists. Microscopic examination was routinely carried out by pathologists to exclude the presence of brain atrophy or other alterations in all subjects. Samples were then rapidly cooled at 4 mC and immediately processed for AC assays. For [$H]8-OH-DPAT binding studies, tissue samples were first frozen in liquid nitrogen and then stored at k80 mC until assay, which was performed within 2 wk.
[
H]8-OH-DPAT binding assay
The binding of [$H]8-OH-DPAT (Amersham, UK, specific activity, 222 Ci\mmol) was carried out in order to measure the K I (inhibition constant, n) values of the tested 5-HT "A receptor compounds : some of them (flibanserin, WAY-100135) have never been evaluated in human brain tissues. [$H]8-OH-DPAT saturation experiments and competition-binding studies were performed as described previously, by incubating membrane homogenates for 15 min at 37 mC (Marazziti et al., 1994) .
AC activity
Partially purified membrane fractions from individual brain samples were prepared as follows : tissue blocks were homogenized by hand (20-30 strokes) in a glass potter Teflon homogenizer in 50 vols. (w\v) of a 10 m Hepes-NaOH buffer (Hepes buffer), pH 7n4, containing 0n32  sucrose, and centrifuged twice (1000 g for 10 min and 13 500 g for 20 min at 4 mC). The last pellet was resuspended in 50 vols. (w\v) of Hepes buffer without sucrose and centrifuged at 35 000 g for 20 min at 4 mC. The final pellet was suspended in the same volume of Hepes buffer and incubated for 15 min at 24 mC. AC activity was measured in a reaction mixture of 50 m Hepes buffer, 0.5 m ATP, 2 m MgCl # , 1 m cyclic AMP (cAMP), 0.5 m isobutyl-methyl-xantine (IBMX), 50 U\ml creatine phosphokinase and myokinase, 5 m creatine phosphate, 0.04 m GTP and 1-2 µCi [α-$#P]-ATP, corresponding to 2-4i10' cpm per tube (Amersham, UK ; specific activity, 30 Ci\mmol), both with and without (basal activity) 100 µ forskolin. The final volume of reaction mixture was 150 µl, composed of 50 µl of membranes (%30 µg protein\sample), 50 µl of the compound's solutions, consisting of agonists : flibanserin (0n01 n-10 µ, Boehringer Ingelheim, Milan, Italy), buspirone (0n01 n-10 µ, RBI, Natick, USA), 5-HT (0n01 n-10 µ, Sigma-Aldrich, Milan, Italy), and antagonists : (p)-WAY-100135 (50-900 n, Boehringer Ingelheim), pindobind 5-HT "A (12n5-25 n, RBI), as well as 50 µl of the reaction mixture. The reaction was started by adding membranes and carried out by incubating samples for 15 min at 24 mC. Proteins were evaluated according to Peterson's method (Peterson, 1977) , using bovine serum albumin as the standard. The reaction was stopped by placing samples in an ice bath and adding an ice-cold solution of 120 m zinc acetate and 144 m Na # CO $ , as described by Johnson et al. (1994) . The stop 5-HT "A receptor function in the human brain solution of zinc acetate contained 10 000-15 000 cpm\ sample of [$H]cAMP (Amersham, UK ; specific activity, 27 Ci\mmol) in order to monitor column recovery. The formation of ZnCO $ into assay tubes caused the precipitation of residual ATP through a centrifugation step at 2700 g for 8 min. Supernatants containing both [α-$#P]-cAMP and [$H]cAMP were then passed through doublestep Dowex-Alumina chromatography.
Data analysis
Drug competition-binding data were analysed with the iterative curve-fitting computer programs -.
Equilibrium-binding parameters in the three brain areas were represented as B max , maximal binding capacity (fmol\mg protein) and K d , dissociation constant (n). For evaluating AC activity (pmol cAMP\mg protein) Salomon's equation (1979) was used. Concentrationresponse curves of buspirone, flibanserin and 5-HT on forskolin-activated AC were analysed using the GraphPad computer program (GraphPad Software Inc., San Diego, CA, USA) in order to estimate EC &! (concentration of drug causing 50 % inhibition of enzyme activity, n) and maximal inhibition (efficacy, E max , %) values. The variability of data in the hippocampus was higher than in the cortex and raphe, and thus variances were not homogeneous. Therefore, the Wilcoxon non-parametric test was used to evaluate differences between basal, forskolinstimulated enzyme activity or agonist inhibition (as pmol\min . mg protein) in each brain area. A paired t test was instead used to evaluate agonist inhibition, by normalizing AC activity at the E max agonist concentration to percent of forskolin stimulation (considered to be 100 %). An unpaired t test was applied to test differences between the E max values of agonist and the endogenous ligand (5-HT). Statistical significance was preset at α l 0n05.
Correlations between basal, forskolin-stimulated AC activity, agonist effects, subject's age and post-mortem delay, were performed using Pearson's method. All analyses were performed using the GraphPad Software Inc.
Results
Saturation binding experiments (meanp... of three individual brain samples performed in duplicate) showed that the B max (fmol\mg protein) of [$H]8-OH-DPAT in the raphe nuclei was 38p1 and the K d (n) was 7n7j0n26. Scatchard analysis of the data revealed the existence of a single population of binding sites. These values are quite consistent with those previously obtained by our research group with [$H]8-OH-DPAT in the prefrontal cortex (B max l 51p3n5; K d l 4n8p0n6) and in the hippocampus (B max l 69p4n6; K d l 3n9p0n6) (Marazziti et al., 1994) . Table 1 Results of AC experiments showed that the basal AC activity (pmol cAMP\mg protein) (meanp...) was 121p18n8 in the prefrontal cortex (n l 16), 95p20n8 in the hippocampus (n l 16) and 107n8p18n2 in the raphe nuclei (n l 18). The incubation of membranes with forskolin increased adenylyl activity (pmol cAMP\mg protein) significantly ( p 0n001) in the three tested regions, up to 310p51n5 in the prefrontal cortex, 211p52 in the hippocampus and 241p45 in the raphe, representing the 253, 227 and 250 % of the basal values, respectively. As shown in Table 2 , flibanserin, up to a concentration of 10 µ, had no effect on forskolinstimulated AC activity in the raphe nuclei, while reducing it significantly in the prefrontal cortex (from 318p86n4 to Table 2 . Inhibitory effects of flibanserin, buspirone and 5-HT on forskolin-stimulated AC activity in the human brain
Prefrontal cortex 28n5p10n2 18n5p2n3 b 10 000 -5n6p1n6 1 2 p0n9 b Hippocampus 3n5p3n1 1 9 n8p4n0 a 10 000 -0n16p0n04 6n9p0n9 a Raphe 10 000 -3n0p2n8 1 1 n7p1n9 6 n8p1n7 1 3 n7p0n7
Values represent the meanp... of individual brain samples [prefrontal cortex : flibanserin (n l 8), buspirone (n l 4), 5-HT (n l 4) ; hippocampus : flibanserin (n l 6), buspirone (n l 3), 5-HT (n l 4) ; raphe : flibanserin (n l 7), buspirone (n l 6), 5-HT (n l 4)]. EC &! (n), concentration of drug causing 50 % inhibition of enzyme activity (drug potency). E max (%), maximal response (drug efficacy), expressed as percentage of maximal drug inhibition with respect to forskolinstimulated AC activity (considered to be 100 %). a Significantly greater E max of flibanserin than that of 5-HT in the hippocampus ( p l 0n035). b Nearly greater E max of flibanserin than that of 5-HT in the cortex ( p l 0n09).
252p67n8, p 0n01) and in the hippocampus (from 246p137n2 to 202p112n3, p 0n05). Flibanserin displayed a significantly greater E max than 5-HT in the hippocampus, while in the cortex this difference was not quite significant ( p l 0n09). Buspirone was active only in the raphe, by inhibiting enzyme activity from 312p106 to 282p99 ( p 0n05). Despite buspirone E max values were lower than those reported for 5-HT, this difference did not reach statistical significance. Normalized data for flibanserin and buspirone, plotted as percent of forskolinstimulated AC activity (100 %) in the three brain regions, are illustrated in Figure 1(a, b) . A representative doseresponse curve of flibanserin and buspirone obtained in the same area of the same subject is shown in Figure 2 150 n) was able to shift the dose-response curve of flibanserin in the hippocampus rightwards (Figure 4 ). These studies of dose-response curve antagonism were done by using two samples for each area. Since four more samples were left, we used another 5-HT "A antagonist (pindobind 5-HT "A ) to evaluate the mechanism of action of flibanserin and buspirone in reducing forskolin-stimulated AC. We used pindobind 5-HT "A at 12n5 and 25 n, since the affinity of this compound for 5-HT "A receptors was approx. 5 n in the tested human brain regions 
Discussion
In the past decade, increasing evidence has been accumulated for the involvement of the 5-HT "A receptor system in depression. Thus, the study of the pharmacology of this receptor in the CNS seems relevant for elucidating the molecular substrates and mechanisms which may underlie depression.
The results of this study, assessed in post-mortem human brain, show that two 5-HT "A receptor agonists, flibanserin and buspirone, produced different effects on forskolin-stimulated AC activity depending on the brain region examined. Flibanserin was active in the prefrontal cortex and hippocampus while being inactive in the raphe. Conversely, buspirone was slightly but significantly active in the raphe but not in the cortex or hippocampus. The effects of flibanserin in the cortex and those of buspirone in the raphe nuclei were mediated by the activation of 5-HT "A receptors, as shown by the antagonism of WAY-100135 and pindobind 5-HT "A . The mechanism of the action of flibanserin in reducing forskolin-stimulated AC compounds were able to displace the 5-HT "A receptor binding by [$H]8-OH-DPAT. Since we have previously observed that 8-OH-DPAT was equally active in inhibiting AC activity in the same human brain regions (Palego et al., 1999) , flibanserin and buspirone seem to produce a dissection in the pharmacology and function of central 5-HT "A receptors. The fact that buspirone acts as an antagonist in the human hippocampus seems surprising, since it has been found to act as a partial agonist in transfected cell lines (Newman-Tancredi et al., 1992) . It seems likely that regional differences in drug action on 5-HT "A receptors can occur in humans. Recent lines of evidence in animals also support this view. Regiondependent changes in 5-HT "A receptor activated Gproteins have been observed in rat brain following chronic buspirone. In fact, this drug was able to desensitize 5-HT "A receptors in dorsal raphe without significant changes of cortical and hippocampal receptors (Sim-Selley et al., 2000) . In addition, it has interestingly been observed that a region-dependent altered regulation of 5-HT "A receptor activity can occur in 5-HT transporter knockout mice, similarly to that observed with chronic treatment with SSRIs, suggesting different adaptive response of this receptor subtype within the brain (La Cour et al., 2001) . Flibanserin has been reported to bind also to 5-HT #A receptors, with a K I of 133 n in the rat and 115 n in the human brain (D. Marazziti, unpublished observations). It has been also observed that 5-HT "A and 5-HT #A receptors exert an opposite effect on neuronal membrane potential (Araneda and Andrade, 1991) . Therefore, it cannot be excluded that the interaction with both subtypes may account for the regional differences of flibanserin reported here. Experiments with selective 5-HT #A receptor antagonists should be performed to exclude this possibility. The differences in 5-HT "A receptor density in these brain regions cannot account for the heterogeneous behaviour of flibanserin and buspirone, in fact buspirone was active in the raphe where the receptor density seems to be slightly lower than in the cortex and hippocampus. Interestingly, the 5-HT "A B max value in the human raphe seems to be much lower than that reported in the rat raphe (Johnson et al., 1997) . Comparison of buspirone and flibanserin E max values with those of the 5-HT endogenous ligand revealed that buspirone had a lower E max value than 5-HT, but this difference did not reach the statistical significance. Flibanserin displayed a significantly greater E max value than 5-HT in the hippocampus, and to a lesser extent in the cortex (almost significant). Similar data have already been observed in the rat brain (Borsini et al., 1995a) . The reported EC &! mean values of flibanserin in the hippocampus and buspirone in the raphe (3n5 and 3n0 n, respectively) are so different from affinity mean values obtained by these compounds in [$H]8-OH-DPAT binding assays (15 and 98n3 n, respectively). The same is true for 5-HT ; in fact, in the hippocampus, 5-HT displayed a K I value of 6n8 n, but it reduced forskolin-stimulated AC with a potency value of 0n16 n. Such discrepancies seem to be consistent, since they have already been observed (Palego et al., 1999 (Yocca et al., 1992) . Nevertheless, the fact that EC &! agonist values are lower than their K I values is not conclusive for spare 5-HT "A receptors, as already observed for β-adrenoceptors (Johnson et al., 1979) . Further, other authors reported no spare receptors for 5-HT "A -mediated inhibition of AC in the rat hippocampus (Yocca et al., 1992) . In addition, NaCl was not used in AC experiments : it is worth noting that the presence of NaCl has been reported to provoke a lower degree of agonist-mediated inhibition of forskolin-activated AC activity (Newman, 1994) . Thus, the unusual agonism\antagonism profile observed in the human hippocampus may imply that 5-HT "A receptors in this area are somehow different, as has been suggested for rats (Ne! nonene! et al., 1996) . However, one cannot exclude the possibility that the discrepancy between EC &! and E max values may depend on inter-subject variability, since agonism, antagonism and binding experiments were carried out in different autopsy subjects. It should also be taken into account that the mean age of autopsy subjects was 70 yr. Concerning the limits due to the use of postmortem tissues, we observed a higher variability of data in the hippocampus than in the cortex and raphe, which cannot exclude a potential influence of post-mortem degradation on the present results. However, no significant correlation was found between agonist EC &! , E max , age and post-mortem delay, except a significant positive correlation for buspirone in the raphe. Taken together these findings give initial support to the belief that the pharmacology of 5-HT "A receptors is also heterogeneous in humans, as reported in animals. The heterogeneity might derive from different RNA editing processes, different protein glycosylation or region-dependent coupling to G proteins (Anthony and Azmitia, 1997 ; Borsini et al., 1995a) . In support of the latter hypothesis, some authors have recently suggested that the reserve of G α i subtypes or AC isoforms can strongly modify the way 5-HT "A receptors activate the AC pathway Liu et al., 1999) . This might also explain why 5-HT "A receptors are linked to AC in the human raphe (present results) but not in the rat raphe (Clarke et al., 1996) , or why buspirone may reduce AC in animals (see Borsini, 1998) , but not in the human hippocampus (present results). Finally, our results may have clinical implications. They would explain why buspirone is not apparently a fast-acting antidepressant and exerts a major role in the treatment of anxiety disorders, where 5-HT "A autoreceptors are supposed to be hypoactive, and 5-HT "A postsynaptic receptors to be hyperactive (Schreiber and De Vry, 1993) . Our results would also support the hypothesis of flibanserin as a fast-acting antidepressant drug D'Aquila et al., 1997) . In fact, to be fastacting, pharmacological data have suggested that an antidepressant should have a selective agonistic effect on post-synaptic 5-HT "A receptors . Anyway, it must be pointed out that, at least in animals, it seems that 5-HT "A receptors may also activate the G o protein-K + channel system (Clarke et al., 1996) . Thus, the fact that buspirone is inactive in reducing AC in both the cortex and hippocampus while flibanserin, being inactive in the raphe, cannot rule out the possibility that these two compounds may have some activity on other 5-HT "A -related second-messenger mechanisms in those brain regions. This can also explain the apparent discrepancy between our results and the observed in-vivo electrophysiological response of flibanserin in the rat dorsal raphe or buspirone in the rat hippocampus (Rueter et al., 1998 ; Tada et al., 1999) . A possible extension of the present study would consist of investigating the degree of AC inhibition of flibanserin and buspirone on a G proteindependent mechanism of AC activation, such as that mediated by PGE " . In conclusion, our study suggests that the human 5-HT "A receptors located in different brain regions, despite similar [$H]OH-DPAT binding profiles, present a different functional pharmacology at the level of the inhibition of forskolin-stimulated AC activity.
